Stocktoria
NEUROCRINE BIOSCIENCES INC NBIX
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 1996-05-23
NEUROCRINE BIOSCIENCES INC financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.9B | $2.4B | $1.9B | $1.5B | $1.1B |
| SG&A expense | $1.2B | $1.0B | $887.6M | $752.7M | $583.3M |
| Operating income | $619.1M | $570.5M | $250.9M | $249.0M | $102.5M |
| Interest expense | — | — | $4.6M | $7.1M | $25.8M |
| Income tax | $226.8M | $144.7M | $82.4M | $59.4M | $11.8M |
| Net income | $478.6M | $341.3M | $249.7M | $154.5M | $89.6M |
| EPS (diluted) | $4.67 | $3.29 | $2.47 | $1.56 | $0.92 |
| Operating cash flow | $782.7M | $595.4M | $389.9M | $339.4M | $256.5M |
| Free cash flow | $748.7M | $557.2M | $361.6M | $322.9M | $233.1M |
| Cash & equivalents | $713.0M | $233.0M | $251.1M | $262.9M | $340.8M |
| Inventory | $69.0M | $57.4M | $38.3M | $35.1M | $30.5M |
| Total assets | $4.6B | $3.7B | $3.3B | $2.4B | $2.1B |
| Total liabilities | $1.4B | $1.1B | $1.0B | $660.9M | $698.5M |
| Shareholders' equity | $3.3B | $2.6B | $2.2B | $1.7B | $1.4B |
Source: SEC EDGAR filings · CIK 0000914475 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.